Our location
Geleen – new mRNA/LNP services and manufacturing
At our site in Geleen, Lonza operates cell and gene therapy process development and manufacturing, mRNA/LNP process and analytical development labs, as well as clinical cGMP capabilities. The facility includes more than 30,000 square feet of laboratory, cGMP manufacturing and office space. The expansion supports the manufacturing of non-GMP product suitable for formulation development and toxicology studies, as well as cGMP product for early and late-stage clinical trials. The expanded development services at the Geleen (NL) site are available with cGMP readiness scheduled in the first quarter 2024.
Scaling lipid nanoparticle manufacturing can impact critical attributes like particle size, encapsulation efficiency, and reproducibility. As leading lipid manufacturers, we address these challenges by strictly controlling critical process parameters and applying proprietary scalable technologies to maintain consistent quality from the lab to commercial scale.
We monitor impurities including residual DNA template, double-stranded RNA, truncated transcripts, enzymes, and lipid-related degradation products. Our LNP encapsulation services include the process- and product-related testing that supports product safety and purity.
